In a recent study by Cosman and colleagues, romosozumab — a humanized monoclonal antibody targeting sclerostin — is shown to reduce the risk of vertebral and clinical fractures at 12 months compared with placebo. However, the low fracture risk of study participants necessitates the completion of an on-going clinical trial before romosozumab can be fully adopted into clinical practice.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Romosozumab in osteoporosis: yesterday, today and tomorrow
Journal of Translational Medicine Open Access 27 September 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Baron, R. & Kneissel, M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19, 179–192 (2013).
Appelman-Dijkstra, N. M. & Papapoulos, S. E. Sclerostin inhibition in the management of osteoporosis. Calcif. Tissue Int. 98, 370–380 (2016).
Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532–1543 (2016).
McClung, M. R. et al. Effects of 2 years of treatment with romosozumab followed by 1 year of denosumab or placebo in postmenopausal women with low bone mineral density. J. Bone Miner. Res. 29 (Suppl. 1), S53 (2014).
Black, D. M. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809–1822 (2007).
Bone, H. G. et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the long-term odanacatib fracture trial. Osteoporos. Int. 26, 699–712 (2015).
Harris, S. T. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282, 1344–1352 (1999).
Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009).
Kolata, G. Fearing rare side effects, millions take their chances with osteoporosis. The New York Times http://www.nytimes.com/2016/06/02/health/osteoporosis-drugs-bones.html (2016).
Khosla, S. & Shane, E. A crisis in the treatment of osteoporosis. J. Bone Miner. Res. 31, 1485–1487 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.E.P. has received consulting and speaking fees from Amgen and UCB, and consulting fees from Mereo Biopharma.
Rights and permissions
About this article
Cite this article
Papapoulos, S. Romosozumab — getting there but not quite yet. Nat Rev Endocrinol 12, 691–692 (2016). https://doi.org/10.1038/nrendo.2016.179
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2016.179
This article is cited by
-
Romosozumab in osteoporosis: yesterday, today and tomorrow
Journal of Translational Medicine (2023)
-
Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway
Nature Reviews Endocrinology (2018)
-
Unmasking romosozumab
Osteoporosis International (2017)